专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20120288482A1 THERAPEUTIC AGENT (Y-39983) FOR CORNEAL ENDOTHELIAL DYSFUNCTION 审中-公开
标题翻译：治疗药物（Y-39983）用于角膜内膜功能障碍
公开(公告)号：US20120288482A1
公开(公告)日：2012-11-15
申请号：US13519682
申请日：2010-12-28
申请人： Hiroaki Takahashi , Yuji Sakamoto , Tetsuo Kida , Takeshi Tarui
发明人： Hiroaki Takahashi , Yuji Sakamoto , Tetsuo Kida , Takeshi Tarui
IPC分类号： A61K31/437 , A61K35/44 , A61P27/02
CPC分类号： A61K31/437 , A61K9/0048 , A61K9/08 , C12N5/0621 , C12N2501/999
摘要： The present invention aims to provide a means for effectively and conveniently treating diseases wherein corneal endothelial cells poor in proliferative capacity in vivo are damaged. The present invention provides a therapeutic agent for corneal endothelial dysfunction containing (R)-(+)-N-(1H-pyrrolo [2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide or a pharmacologically acceptable salt thereof (compound (Ia)) as active ingredient, an agent for promoting adhesion of corneal endothelial cells, containing compound (Ia), a culture medium for corneal endothelial cells, containing the agent for promoting adhesion, an implant for corneal endothelial keratoplasty, containing corneal endothelial cells, scaffold and compound (Ia), and a production method of a corneal endothelial preparation, including a step of cultivating corneal endothelial cells using the culture medium.
摘要翻译：本发明旨在提供一种有效且方便地治疗疾病的手段，其中体内增殖能力差的角膜内皮细胞被破坏。本发明提供了含有（R） - （+） - N-（1H-吡咯并[2,3-b]吡啶-4-基）-4-（1-氨基乙基）苯甲酰胺的角膜内皮功能障碍的治疗剂 -3983>或其药理学上可接受的盐（化合物（Ia））作为活性成分，用于促进角膜内皮细胞粘附的试剂，含有化合物（Ia），用于角膜内皮细胞的培养基，其含有促进粘附的试剂，用于角膜内皮角膜移植术的植入物，其包含角膜内皮细胞，支架和化合物（Ia），以及角膜内皮制剂的制备方法，包括使用培养基培养角膜内皮细胞的步骤。

2. 发明授权

US06874675B2 Method for manufacturing printed circuit board 失效
标题翻译：印刷电路板制造方法
公开(公告)号：US06874675B2
公开(公告)日：2005-04-05
申请号：US10616194
申请日：2003-07-09
申请人： Tetsuo Kida , Samuel Kenneth Liem
发明人： Tetsuo Kida , Samuel Kenneth Liem
IPC分类号： C23G1/00 , H05K3/26 , H05K3/34 , B23K1/20
CPC分类号： H05K3/26 , C23G1/00 , H05K3/3489 , H05K2203/0789 , H05K2203/0793 , Y10T29/4913
摘要： A method for manufacturing a printed circuit board includes: washing a land that corresponds to the exposed portion of a copper circuit of a printed circuit board with acidic electrolytic water having a pH of not more than 5 to remove an oxide; treating the land with basic electrolytic water having a pH of not less than 9 to prevent oxidation; and soldering electronic components to the land. The portion to be soldered is treated with the electrolytic water beforehand, thereby improving soldering at low cost without any adverse effect on the environment.
摘要翻译：印刷电路板的制造方法包括：用pH5以下的酸性电解水清洗与印刷电路板的铜电路的露出部分相对应的焊盘，以除去氧化物; 用pH不小于9的碱性电解水处理土地以防止氧化; 并将电子元件焊接到土地上。预先用电解水处理要焊接的部分，从而以低成本改善焊接，而不会对环境产生不利影响。

3. 发明申请

US20110054031A1 Ophthalmic NSAIDS as Adjuvants 审中-公开
标题翻译：眼科NSAIDS作为佐剂
公开(公告)号：US20110054031A1
公开(公告)日：2011-03-03
申请号：US12867470
申请日：2009-02-19
申请人： Tim McNamara , Simon P. Chandler , Tetsuo Kida
发明人： Tim McNamara , Simon P. Chandler , Tetsuo Kida
IPC分类号： A61K31/196 , A61P27/00 , A61P29/00
CPC分类号： A61K31/196
摘要： The disclosure provides methods and ophthalmic NSAIDs as adjuvants to VEGF inhibitors useful for treating retinal disorders, including but not limited to wet AMD, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, and branch retinal vein occlusion.
摘要翻译：本公开提供了用于治疗视网膜病症（包括但不限于湿性AMD，糖尿病性视网膜病变，糖尿病性黄斑水肿，视网膜中央静脉阻塞和视网膜分支静脉闭塞）的VEGF抑制剂的方法和眼用NSAID作为VEGF抑制剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式